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Abstract
Background: Corticosteroid resistance is a major barrier to effective treatment of COPD. We have shown that the
resistance is associated with decreased expression of glucocorticoid receptor (GCR) by senescent CD28nullCD8+
pro-inflammatory lymphocytes in peripheral blood of COPD patients. GCR must be bound to molecular chaperones
heat shock proteins (Hsp) 70 and Hsp90 to acquire a high-affinity steroid binding conformation, and traffic to the
nucleus. We hypothesized a loss of Hsp70/90 from these lymphocytes may further contribute to steroid resistance
in COPD.
Methods: Blood was collected from COPD (n = 10) and aged-matched controls (n = 10). To assess response to
steroids, cytotoxic mediators, intracellular pro-inflammatory cytokines, CD28, GCR, Hsp70 and Hsp90 were determined
in T and NKT-like cells in the presence of ± 10 μM prednisolone and 2.5 ng/mL cyclosporine A (binds to GCR-Hsp70/90
complex) using flow cytometry, western blot and fluorescence microscopy.
Results: A loss of expression of Hsp90 and GCR from CD28null CD8+ T and NKT-like cells in COPD was noted
(Hsp70 unchanged). Loss of Hsp90 expression correlated with the percentage of CD28null CD8+ T and NKT-like
cells producing IFNγ or TNFα in all subjects (eg, COPD: R = −0.763, p = 0.007 for T-cell IFNγ). Up-regulation of
Hsp90 and associated decrease in pro-inflammatory cytokine production was found in CD28nullCD8+ T and NKT-like
cells in the presence of 10 μM prednisolone and 2.5 ng/mL cyclosporine A.
Conclusions: Loss of Hsp90 from cytotoxic/pro-inflammatory CD28nullCD8+ T and NKT-like cells could contribute
to steroid resistance in COPD. Combination prednisolone and low-dose cyclosporine A therapy inhibits these
pro-inflammatory cells and may reduce systemic inflammation in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of death worldwide and existing treatments,
such as anti-inflammatory corticosteroids, have no proven
disease modifying effect [1] although a reduction in ex-
acerbation rates and improved health status has been
reported [2]. The mechanisms underlying this resistance
are largely unknown, particularly in lymphocytes [2]. It
has been suggested that CD8+ T cells are the central regu-
lator of the inflammatory network in COPD [3]. CD8+ T
cell deficient mice had a blunted inflammatory responses
and did not develop emphysema when exposed to long-
term cigarette smoke [3]. We have reported increased pro-
duction of pro-inflammatory cytokines and expression of
cytotoxic mediators granzyme b and perforin in CD8+ T
cells in the peripheral blood and lungs [4] of current and
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ex-smoker COPD patients compared to healthy smokers
and never-smokers [5].
Our research has focused on identifying the lymphocyte
subset/s resistant to current therapeutics and we have
made several important discoveries. We have shown that
COPD is associated with increased CD28nullCD8+ senes-
cent cells in the peripheral blood of both current and ex-
smoker COPD subjects, and showed these cells are more
cytotoxic/pro-inflammatory than CD8 +CD28+ cells [6].
NKT-like and NK cells were increased in bronchoalveolar
lavage of COPD patients and associated with increased
cytotoxicity [7]. In this regard, CD8 + CD28null NKT-like
cells have been shown to be more pro-inflammatory and
cytotoxic than CD8 + CD28+ NKT-like cells in other pro-
inflammatory lung diseases [8].
CD28nullCD8+ pro-inflammatory lymphocytes have
decreased levels of histone deacetylase 2 (a nuclear en-
zyme required by corticosteroids to switch off activated
inflammatory genes) [9] and reduced levels of gluco-
corticoid receptor (GCR) [10].
GCR must be bound to the molecular chaperones heat
shock proteins (Hsp) 70 and Hsp90 to acquire a high-
affinity steroid binding conformation, and traffic to the
nucleus [11]. We hypothesized a loss of Hsp70/90 from
these lymphocytes may contribute to steroid resistance
in COPD.
To investigate this hypothesis, we determined whether
peripheral blood CD28null T cells and NKT-like cells
(particularly CD8+) from COPD patients express reduced
levels of Hsp70 and Hsp90 and whether loss of these mo-
lecular chaperones is associated with a lack of suppression
of cytotoxic mediators or pro-inflammatory cytokines pro-
duced in response to steroid treatment. The immunosup-
pressant, cyclopsorin A (CsA) binds to the GCR-Hsp90
complex but not Hsp70 [12]. We therefore also investi-
gated the effect of CsA in combination with the cor-
ticosteroid prednisolone, on Hsp70/90 and associated
pro-inflammatory cytokine expression by lymphocyte
subsets.
Methods
Patient and control groups
COPD volunteers were specifically recruited for the study
and informed consent obtained. There was no exacerba-
tion of COPD for 6 weeks prior. Subjects with other co-
existing lung disease or malignancy or aged greater than
75y were excluded. Ethics approval was obtained from
the Royal Adelaide Hospital and the experiments were
conducted with the understanding and the written con-
sent of each participant. COPD was diagnosed using the
GOLD criteria with clinical correlation (mild COPD:
FEV1/FVC < 70 % but FEV1 ≥ 80 % predicted; moderate
COPD FEV1 50 % ≤ 80 % predicted, severe COPD FEV1
30 % ≤ 50 % predicted, very severe COPD FEV1 < 30 %
predicted) [13]. Blood was collected from 10 patients with
COPD (Table 1) all of whom were ex-smokers (at least
one year) with an average of 37 pack years. No patients
were receiving oral corticosteroids although 8/10 patients
were taking inhaled steroids.
Blood was also obtained from 10 aged-matched non-
smoking volunteers (Table 1) with normal lung function.
These were healthy, recruited volunteers with no history
of airways disease. All subjects underwent spirometry as
part of their routine clinical assessment. Venous blood
was collected into 10 U/mL preservative free sodium hep-
arin (DBL, Sydney, Australia), and maintained at 4 °C until
processing within 4 h. All patients were submitted to the
same protocol and analysis performed retrospectively.
Hsp70, granzyme b and perforin expression in T and
NKT-like cell subsets
Hsp70 was constitutively expressed in lymphocyte sub-
sets, however stimulation of cells was required for expres-
sion of Hsp90 as previously shown, hence mimicking
Hsp90 induction following stress response [14]. To deter-
mine expression of Hsp70 and cytotoxic mediators gran-
zyme b and peforin in CD8+ and CD8-T and NKT-like
cells, aliquots of blood were added to FACS tubes and red
blood cells were lysed using FACSLyse (BD Biosciences,
Sydney, Australia) as described previously [9]. After
10 min, tubes were centrifuged at 300 g for 5 min,
supernatant discarded and leucocytes permeabilised using
FACSPerm (BD) as previously reported [9]. Cells were
then washed with wash buffer (0.5 % BSA in Isoflow
(Beckman Coulter, Sydney, Australia)), and appropriately
diluted monoclonal antibodies (Mabs) added as previously
reported [15]: anti-Hsp70 AF488 (clone W27, Biolegend,
Sydney, Australia), perforin PE (BD), CD3 perCP.CY5.5
(BD), CD28 PECY7 (BD), CD56 APC (Beckman Coulter),
CD8 APC.CY7 (BD), granzyme B V450 (BD) and CD45
V500 (BD). After washing cells in wash buffer, centrifuga-
tion and decanting, cells were analyzed within 1 h on a
FACSCanto II flow cytometer using FACSDiva software
(BD). Samples were analyzed by gating lymphocytes using
CD45 staining versus side scatter (SSC). A minimum of
350,000 low SSC events were acquired in list-mode format
for analysis. T cells were identified as CD3 + CD56-CD45+
Table 1 Demographic details of the COPD and control group
Subjects Controls COPD
No. of subjects 10 10
Age (years) 49 (41–57) 58 (42–64)*
FEV1, % pred 108.4 (91–110) 60.1 (44–96)*
FEV1/% FVC 96 (84–108) 58 (43–73)*
Male/Female 8/6 6/4
Data showing median (range)
Abbreviations: FEV1 forced expiratory volume in 1 s, FVC forced vital capacity;
*p < 0.05 compared to controls
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and NKT-like cells identified as CD3 + CD56+ CD45+ low
FSC/SSC events [9].
Hsp90, GCR and intracellular cytokine expression in T and
NKT-like cell subsets
To determine co-expression of Hsp90 and GCR with
intracellular cytokines in CD8+ and CD8-T and NKT-
like cells, aliquots of blood were stimulated as previously
reported [3] with phorbol myristate acetate (25 ng/mL)
(Sigma, Sydney, Australia) and ionomycin (1 μg/mL)
(Sigma) in the presence of brefeldin A (1 μg/mL) (Sigma)
and the tubes incubated in a humidified 5 % CO2/95 % air
atmosphere at 37 °C. The addition of brefeldin A had no
effect on Hsp90 or GCR expression in these experiments
(not shown). At 16 h, 100 μL 20 mM EDTA/PBS was
added to the culture tubes, followed by vigorous vortexing
for 20 s to remove adherent cells. Red blood cells were
lysed and cells were permeabilised as described previously
[3]. Two mL 0.5 % bovine serum albumin (Sigma/Aldrich,
Sydney, Australia)/Isoflow (Beckman Coulter, Sydney,
Australia) was then added and the tubes centrifuged at
300 × g for 5 min. After decanting the supernatant, Fc re-
ceptors were blocked with 10 μL human immunoglobulin
(Intragam: CSL, Parkville, Australia) for 10 min in the
dark at RT. Cells were stained with appropriately diluted
anti-Hsp90 Mab (clone AC88, Abcam, Sydney, Australia)
as described above. Following washing of cells, cells were
stained with rat anti-mouse IgG1 PE (BD) for 15 min in
the dark at RT. Cells were stained with appropriately
diluted anti-GCR Mab (clone 5E4, Serotec, Sydney,
Australia) as described previously [10]. Cells were then
washed and stained with rat anti-mouse IgG1 V450
(BD) for 15 min in the dark at RT. Cells were further
washed and appropriately diluted Mabs to IFNγ FITC,
TNFα FITC (BD), CD3 perCP.CY5.5 (BD, Sydney,
Australia), CD28 PECY7 (BD), CD56 APC (Beckman
Coulter, Sydney, Australia), CD8 APC.CY7 (BD) and
CD45 V500 (BD) added for 15 min in the dark at RT.
Following a final wash, cells were analyzed within 1 h
on a FACSCanto II flow cytometer using FACSDiva
software (BD). Samples were analyzed by gating lym-
phocytes using CD45 staining versus side scatter (SSC).
A minimum of 350,000 low SSC events were acquired in
list-mode format for analysis. T cells were identified as
CD3 +CD45+ and NKT-like cells identified as CD3 +
CD56+ CD45+ low FSC/SSC events.
Hsp90 expression in CD28+ and CD28null T cells by
Western Blot
Expression of Hsp90 has not previously been validated
using flow cytometry therefore confirmation of Hsp90
staining was determined using western blot and immuno-
fluorescence. PBMC were isolated from blood of cohorts
of control (n = 2) and COPD patients (n = 3) by standard
density gradient centrifugation and cells re-suspended at
1 × 107 mL in RPMI 1640 medium. Following stimulation
as described above, 5 μL of appropriately diluted CD3
perCP.CY5.5 (BD), CD28 PE.CY7 (BD), CD56 APC
(Beckman Coulter), CD8 APC.CY7 (BD) and CD45
V500 (BD) Mabs were added for 15 min in the dark at
room temperature. Cells were washed and resuspended
in 1 mL RPMI and CD28+ and CD28null, CD8+ and
CD8-T cells were immediately sorted on a FACSAria
flow cytometer (BD).
Equal numbers of sorted CD28+ and CD28 null T cells
were lysed using M-Per mammalian cell protein lysis re-
agent with Halt® protease inhibitor cocktail (both Thermo
Scientific, Victoria, Australia). Protein samples were
quantified using the DC protein assay (Bio-Rad, Victoria,
Australia), and 10 μg electrophoresed using Novex®
4–12 % gradient Bis-Tris denaturing gels (Life Technolo-
gies, Victoria, Australia) and electroblotted to Trans-Blot®
Turbo nitrocellulose membrane (Bio-Rad). Membranes
were blocked in 5 % diploma skim milk, washed, then
incubated overnight at 4 °C with anti-human Hsp90
(1:2000), followed by a 1 h incubation at RT with horse
radish peroxidase-labelled anti-mouse secondary antibody
(R&D Systems, MN, USA). Chemiluminescent imaging
was performed using the LAS-3000 platform, and histo-
gram analysis performed using the Multigauge software
package (both FugiFilm, Tokyo, Japan). Mouse-anti Hu-
man β-actin antibody (Sigma-Aldrich, MO, USA) was
used to correct for loading error for histogram analyses.
Immunoprecipitation
Immunoprecipitation, in conjunction with western ana-
lysis were used to confirm Hsp90 protein in complex
with the GCR. Equal numbers of sorted CD28+ and
CD28 null T-cells were isolated from a patient with
COPD and were lysed in protein extraction buffer, in the
presence of protease inhibitors (as above). Protein sam-
ples were precipitated using protein G Dynabeads® (Life
Technologies, Victoria, Australia) labelled with GCR
monoclonal antibody and the eluates were probed for
Hsp90 using western analysis (as outlined above). Un-
labeled bead controls were also incubated with protein
samples to assess for nonspecific binding.
Hsp90 expression in CD28+ and CD28null T cells by
Fluorescent Microscopy
Fluorescence microscopy was used to validate Hsp90
staining. 1 × 103 sorted CD28+ and CD28 null T cells (as
described above) were added to a Cytospin 4 cytocentri-
fuge (ThermoFisher Scientific, Scorseby, Victoria, Australia)
and centrifuged for 500 g for 5 min. Slides were air dried
for 10 min and cells fixed with 2.5 % formalin in PBS for
10 min. Cytospins were treated with 1 % sodium dodecyl
sulphate (SDS, Sigma Aldrich, Castle Hill, NSW, Australia)
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in PBS for 5 min, followed by 1 h incubation with a
serum-free protein blocker (Dako A/S, Glostrup, Denmark),
overnight incubation at 4 °C with 1/25 diluted Hsp90
monoclonal antibody (Serotec, Abacus ALS, Brisbane,
Australia), then 1 h with AF594-conjugated donkey IgG F
(ab’) 2 fragment polyclonal antibody to mouse IgG
(Abcam, Sapphire Bioscience, Waterloo, NSW, Australia),
and counterstained with DAPI (Sigma-Aldrich). Cells were
washed between incubation with 0.01 M Tris-buffered
saline pH 7.5, containing 0.05 % Tween-20. Immuno-
fluorescence was detected and imaged with a Olympus
IX73 fluorescence microscope (Olympus, Notting Hill,
VIC, Australia). For quantitative analysis, cells from
each cytospin were photographed under a 40× object-
ive in 8 optical fields, selected in the DAPI channel for
bias prevention, the mean fluorescence intensities
measured then in the AF594 channel using the ImageJ
software (NIH, Bethesda, MD, USA) as previously de-
scribed [10].
Effect of drugs on Hsp90, GCR and intracellular IFNγ and
TNFα expression in T and NKT-like cell subsets
The immunosuppressant, CsA binds to the GCR-Hsp90
complex but not Hsp70 [11]. We therefore also inves-
tigated the effect of CsA in combination with the
corticosteroid prednisolone on Hsp90 and associated
pro-inflammatory cytokine expression by lymphocyte
subsets. CsA is a Pgp-1 inhibitor and we have previously
shown that pro-inflammatory cytokine production was
significantly reduced in T and NKT-like cells in the pres-
ence of very low dose cyclosporine A (2.5 ng/mL) [16]. To
determine the effect of these drugs on Hsp90 expression
in pro-inflammatory T and NKT-like cells, aliquots of
blood were mixed in 10 mL sterile tubes with equal vol-
ume of RPMI 10 % FCS and incubated with ± 1 μM pred-
nisolone ± 2.5 ng/mL CsA and the tubes incubated in a
humidified 5 % CO2/95 % air atmosphere at 37 °C for
24 h. Blood cultures were then stimulated as for intra-
cellular cytokine production as described above for 16 h.
Aliquots of blood cultures were then processed as for
intracellular cytokines and HSP90, IFNγ and TNFα ex-
pression as described above.
Statistical analysis
Statistical analysis was performed using the Wilcoxon sign
rank test. For T-cell subsets (CD28null/CD8+/CD3+/CD56
−/CD45+/TNFα+/IFNγ+), a sample size of n = 10 allowed
a power of 98–99.5 % for analysis. Variance was estimated
from our previous studies [4–7]. Correlations were per-
formed using Spearman Rho correlation tests. SPSS
software was applied and differences between groups of
p < 0.05 considered significant.
Results
Increased CD28null CD8+ T and NKT-like cells in COPD
patients
There was a significant increase in CD28nullCD8+ T
cells in patients with COPD compared with healthy
controls (p < 0.05), but no change in CD28nullCD8- T
cells (CD28nullCD8+ T: 56 ± 7.7 (32 ± 7.5); CD28nullCD8-
T: 6.9 ± 3.3 (6.1 ± 4.3) for COPD patients (controls)
(median ± sem) consistent with our previous findings
for CD28null T cells [6]. There was a significant in-
crease in CD28nullCD8+ NKT-like cells in patients with
COPD compared with healthy controls but no change in
CD28nullCD8- NKT-like cells (CD28nullCD8+ NKT-like:
41 ± 6.8 (23 ± 6.6); CD28nullCD8- T: 8.6 ± 3.8 (7.6 ± 3.5)
for COPD patients (controls)).
Hsp70, perforin and granzyme B expression by CD28+
and CD28null T and NKT-like cells
A higher percentage of CD28nullCD8+ T cell and NKT-
cells expressing perforin and granzyme b was found in
COPD patients compared with control subjects (eg.,
44 ± 12 (15 ± 13) p = .031; and 34 ± 11 (13 ± 9) p = .021
for the percentage of CD28null CD8+ T cells express-
ing granzyme b and perforin (median ± sem) from
COPD patients (controls) respectively, consistent with
a previous report [9]. There was no change in perforin
or granzyme b expression in CD28 + CD8+ or CD28 +
CD8-T and NKT-like cells from COPD or control
groups (p > 0.05 for all) also consistent with a previous
report [9].
There was no change in the percentage of
CD28nullCD8+ T cell and NKT-cells expressing Hsp70 in
COPD patients compared with control subjects (p > 0.05
for all) (Table 1). There was no change in Hsp70 expres-
sion between CD28+ or CD28null CD8+ or CD8-T or
NKT-like cells between COPD patients or control sub-
jects (p > 0.05 for all) (Table 2). The was no correlation
between the percentage of any lymphocyte subset ex-
pressing Hsp70 and granzyme b or perforin (p > 0.05
for all).
Hsp90, GCR and intracellular cytokine expression in T and
NKT-like cell subsets
A significant increase in the percentage of CD28nullCD8+
T and NKT-like cells producing IFNγ and TNFα com-
pared with CD28 + CD8+ T and NKT-like cells was noted
in COPD patients and control groups consistent with a
previous report [9, 10] (data not shown).
For both COPD groups and controls, a significantly
lower percentage of CD28nullCD8+ T and NKT-like cells
expressing Hsp90 was found, compared with CD28+ T
and NKT-like cells (data for T cell and NKT-like cell sub-
sets from COPD group shown in Fig. 1) (data for controls
not shown).
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A significantly lower percentage of CD28nullCD8+ T and
NKT-like cells expressing GCR was found, compared with
CD28+ T and NKT-like cells from all groups tested. This is
consistent with previous findings [14] (data not shown).
There was no difference in expression of Hsp90, GCR
or IFNγ by CD28nullCD8+ T and NKT-like cells between
COPD groups and control subjects (p > 0.05 for all).
We found a negative correlation between loss of Hsp90
expression by CD28nullCD8+ T cells and the percentage
of these cells producing IFNγ (Fig. 2a) and TNFα (Fig. 2b)
in the COPD group but not the control group. There was
a negative correlation between loss of Hsp90 expression
by CD28nullCD8+ NKT-like cells and the percentage of
these cells producing IFNγ (R = −.647, P = .039) and TNFα
(R = −.557, P = .043) in the COPD group.
A significant correlation between Hsp90 expression
and GCR expression by CD28nullCD8+ T cells (Fig. 3)
and NKT-like cells (data not shown) was shown, but no
correlation found between any other cell subset (p > 0.05
for all, data not shown).
There was no significant correlation between past smok-
ing history of COPD groups with any cell subset or
Hsp90, GCR or pro-inflammatory cytokine (p > 0.05, data
not shown).
Representative flow cytometry plots showing expression
of IFNγ and Hsp90 expression in CD3 +CD8 + CD28null
and CD3 +CD8 + CD28+ cells and GCR expression in
IFNγ +Hsp90+ and IFNγ +Hsp90-subsets of these cells is
shown in Fig. 4. Note the most pro-inflammatory subset
(producing the most IFNγ) expresses the least GCR (2 %)
and no Hsp90.
Hsp90 expression of CD28+ and CD28null T cells by
Western Blot
Equal numbers of FACS-sorted CD28+ and CD28null T
cells were stained for Hsp90 expression by western
Table 2 Percentage of lymphocyte subsets expressing Hsp70
CD3 + CD8 + CD28null
T-cells
CD3 + CD8 + CD28+
T-cells
CD3 + CD8 + CD56 + CD28null
NKT-like cells
CD3 + CD8 + CD56 + CD28+
NKT-like cells
COPD 15.9 (4–31) 18.8 (3–35) 17.3 (4–36) 14.8 (3–39)
Control 19.7 (5–33) 17.3 (3–33) 15.9 (5–32) 15.9 (2–41)
Data showing median (range)
p > 0.05 for all data compared to controls
Fig. 1 The percentage of CD28+ and CD28null CD8+ (clear bars) and CD8-T cells expressing Hsp90 in patients with COPD. There was a significant
decrease in the percentage of CD8 + CD28null (8 + 28n) T and NKT-like cells expressing Hsp90 (clear bars) compared with CD8 + CD28+ and
CD28 + CD8- T and NKT-like cells (grey bars) (trend for CD8-CD28 + NKT-like cells) and a decrease in Hsp90 expression in CD8 + CD28null compared
with CD8-CD28+ T cells. Box plots present median ± 25th and 75th percentiles (solid box) with the 10th and 90th percentiles shown by
whiskers outside the box.*significantly (p < 0.05) decreased expression compared to controls
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analysis. There was a decrease in the 90 kD band corre-
sponding to the Hsp90 in CD28null T cells compared
with CD28+ T cells (Fig. 5a). Hsp90 expression relative
to β-actin from CD28 null (CD28-) and CD28+ T cells
(median ± sem from 3 experiments) is shown in Fig. 5b.
Hsp90 is in complex with the GCR
Protein precipitation using GCR-labelled beads, and
probed for Hsp90 during western analysis confirmed the
presence of Hsp90-GCR complexes (Fig. 6).
Hsp90 expression in CD28+ and CD28null T cells by
Fluorescent Microscopy
Sorted CD28+ and CD28null T cells were stained for
Hsp90 expression. There was significant positive staining
with Hsp90 in CD28+ T cells compared with CD28null
T cells using fluorescence microscopy (Fig. 7a). Hsp90
staining was mainly located in the CD28+ T cell nucleus
(Fig. 7b).
Hsp90 expression in the cytoplasm and nucleus of
CD28+ T cells compared with CD28 null T cells
To confirm nuclear staining of Hsp90 in CD28+ T cells,
differential expression of Hsp90 in the cytoplasm and
nucleus of CD28+ and CD28null T and NKT-like cells
was performed. There was a significant increase in Hsp90
expression in the nucleus of CD8 +CD28+ cells compared
with CD8 + CD28null cells. Representative flow cytometry
plots showing expression of Hsp90 in CD8 + CD28null
and CD8 +CD28+ T cells in the cytoplasm and nucleus
following stimulation are shown in Fig. 8.
Correlation between Hsp90 by CD28nullCD8+ T cells and
FEV1
There was a correlation between Hsp90 expression by
CD28nullCD8+ T cells and FEV1 (% predicted) from the
COPD group (Fig. 9) but no correlation between Hsp90
expression by any other lymphocyte subset with FEV1
(data not shown).
Effect of drugs on Hsp90 and intracellular cytokine
expression by CD28null CD8+ T and NKT-like cells in
COPD patients
The effect of 1 μM prednisolone on the inhibition of
IFNγ production by CD28null and CD28+ CD8+ and
CD8 − T cells compared with cultures with no drug is
shown in Fig. 10a. There was a significant inhibitory ef-
fect on CD28+ compared with CD28null cells in the
presence of prednisolone and a significant inhibitory ef-
fect on CD28nullCD8- compared with CD28nullCD8+
Fig. 2 There was a significant negative correlation between the
percentage of CD28nullCD8+ T cells expressing Hsp90 and producing
IFNγ in COPD subjects
Fig. 3 There was a significant correlation between the percentage
of CD8 + CD28null T cells expressing Hsp90 and GCR in COPD subjects
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cells (n = 5; median ± sem) (* p < 0.05 for all). The effect
of 1 μM prednisolone (MP) ± 2.5 ng/mL CsA on the in-
hibition of IFNγ production by CD28nullCD8+ T cells
compared with cultures with no drug is shown in
Fig. 10b.
We also showed a significant increase in the per-
centage of CD28nullCD8+ T cells expressing Hsp90 in
the presence of MP, CsA or a combination of both.
Similar results were obtained for upregulation of Hsp90
and inhibition of IFNγ production by CD28+ and
CD28nullCD8+ and CD8-NKT-like cells (ie., results were
similar for all T and NKT-like subsets). Representative dot
plots showing the combined effect of 1 μM prednisolone
and 2.5 ng/mL CsA on the percentage of CD28nullCD8+
Fig. 4 Representative plots showing expression of IFNγ and Hsp90 expression in CD3 + CD8 + CD28null (top plots) and CD3 + CD8 + CD28+
(bottom plots) cells and GCR expression in IFNγ + Hsp90+ (upper right quadrants) and IFNγ + Hsp90-(bottom right quadrants) subsets of these cells.
Note the most pro-inflammatory subset (producing the most IFNγ) expresses the least GCR (2 %) and no Hsp90
Fig. 5 a. Representative Western Blot of equal numbers of sorted CD28+ and CD28null T cells, stained for Hsp90 expression. There was a decrease in
the 90 kDa band corresponding to the Hsp90 in CD28null T cells compared with CD28+ T cells. b. Bar graph showing Hsp90 expression relative to
β-actin from CD28 null (CD28−) and CD28+ T cells (mean ± sem from 3 experiments)
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T and NKT-like cells expressing Hsp90 and IFNγ are
shown in Fig. 11.
The presence of the Hsp90 inhibitor, 17-AAG (2 μM),
negated 75 ± 12 % (median ± sem from 4 experiments) of
the inhibitory effect of CsA and MP on IFNγ and TNFα
by CD8+ and CD8-T and NKT-like cells.
Discussion
This is the first study to show that lymphocyte senes-
cence is associated with loss of molecular chaperone
Hsp90 from CD8 + CD28null T and NKT-like cells. The
loss of Hsp90 was shown to correlate with the cytotoxic/
pro-inflammatory potential of these cells and importantly,
lung function in patients with COPD. Other molecules
have been reported on senescent lymphocytes indicating
our present study may have underestimated the CD8+
phenotype [17].
GCR must be bound to molecular chaperones Hsp70
and Hsp90 to acquire a high-affinity steroid binding
conformation, traffic to the nucleus where engagement
of histone deacetylases (HDACs), particularly HDAC2,
results in reduction of pro-inflammatory gene activation
[17] and our findings of GCR-Hsp90 binding was con-
firmed using immunoprecipitation and western anaylsis.
In this regard we have recently shown a loss of gluco-
corticoid receptor and HDAC2 expression by these sen-
escent lymphocyte subsets [9, 10]. These findings suggest
that multiple factors may be influencing steroid resistance
in these cells. Interestingly, reduced Hsp90 expression
has been shown to be associated with immune T cell
senescence and could be mimicked by mild oxidative
stress similar to that experienced in COPD [18].
Addition of exogenous rHsp90 to purified proteasome
preparations could upregulate the catalytic activity of
the proteasome suggesting loss of Hsp90 contributes
directly to lymphocyte immune senescence [18]. In
contrast, one study showed that nuclear levels of Hsp90
and Hsp70 were increased in cells isolated from in-
duced sputum of stable COPD patients [19]; however,
as most cells in induced sputum are macrophages and
neutrophils, a comparison with lymphocyte subsets in
our present study cannot be made. Hsp90 impairment
has recently been associated with loss of CD28 mol-
ecule in lymphocytes consistent with our current study
[20]. Diminished induction of Hsp90 has been observed
in older subjects regardless of health status, however
these differences were only evident in subjects with a
mean age of 75 years and as such would probably not
account for differences observed in the slightly older
patient group in our study [21].
The correlation between expression of Hsp90 and
GCR in the pro-inflammatory lymphocyte subsets is inter-
esting although puzzling. Although the role of molecular
chaperones in nuclear trafficking of GCR is well estab-
lished [22], a possible link between Hsp90 and GCR ex-
pression is unknown and may be an anomaly of
Fig. 6 Western blot staining (WB) of equal numbers of sorted CD28+ and CD28-T cells following protein immunoprecipitation (IP) using
GCR-labelled beads, and probed for Hsp90 confirmed the presence of Hsp90-GCR complexes
Fig. 7 a. Representative laser confocal images of Hsp90 staining (red) in FACS-sorted CD28null (right) and CD28+ T cells (left). Blue was DAPI
counterstaining. Scale bar = 8 μm. b. The bar graph depicts results of quantitative analysis by ImageJ. Experiments were repeated 3 times,
showing similar results. *** p < 0.05
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senescent lymphocytes. CD8CD28null T and NKT-like
cells express the least Hsp90 and GCR [10] and recently
were shown to express reduced HDAC2 [9]. Further study
of HDAC2 interactions with GCR and Hsp90 in these
pro-inflammatory lymphocyte subsets may also be of
interest. GCR and Hsp90 were shown to be deficient in
the same CD8 + CD28null T and NKT-like cells. If
HDAC2 expression is also reduced in the same senescent
lymphocytes, a combination of drug/s to increase expres-
sion of all three molecules may be required to completely
overcome steroid resistance in these cells.
Senescent CD28null T and NKT-like cells have been
shown to be more pro-inflammatory and cytotoxic than
their CD28 positive counterparts [6, 9, 10], and exhibit a
relative resistance to corticosteroids [10]. Increased pro-
inflammatory CD8+ T cells in peripheral blood and
lungs [4] and an increase in cytotoxic NKT-like and NK
cells in the airways have been shown in COPD patients
compared to healthy and never-smokers [7]. We have
also identified increased CD28nullCD8+ cells in both
current and ex-smoker COPD groups [6]. Our current
study extends this data and demonstrates a negative cor-
relation between the percentage of CD28nullCD8+ T
and NKT-like cells producing pro-inflammatory cyto-
kines IFNγ and TNFα, and the percentage expressing
Hsp90. Another important extension to our studies
would be to determine whether Hsp90 levels in lympho-
cyte subsets are altered in smokers who have not pro-
gressed to COPD and whether there is any correlation
with smoking pack years. We also demonstrated that the
Hsp90 deficient lymphocytes were present in the systemic
circulation of COPD patients. Barnes et al. proposed a
spillover of cells from the lungs into the systemic circula-
tion [2], which suggest these Hsp90 deficient cells may
Fig. 8 Representative flow cytometry plots showing expression of Hsp90 in CD8 + CD28null and CD8 + CD28+ T cells in the cytoplasm and nucleus
following stimulation. There was a significant increase in Hsp90 expression in the nucleus of CD8 + CD28+ cells compared with CD8 + CD28null cells
(p < 0.05 for all, from 5 experiments)
Fig. 9 There was a significant correlation between the percentage of CD8 + CD28null T cells expressing Hsp90 and FEV1 (% predicted) in COPD subjects
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have originated in the lung possibly due to increased levels
of oxidative stress.
Interestingly, we showed that a loss of Hsp90 expression
by CD28nullCD8+ T and NKT-like cells also occurred in
healthy control subjects (Hsp90 expression was the same
in CD28null T and NKT-like cells from both subject
groups), although at decreased numbers compared with
patients with COPD. Lymphocyte senescence and GC
resistance have been described in several other inflam-
matory conditions, such as cardiovascular disease [23],
autoimmune disease [24], arthritis [25], IBD [26], aging
[27] and aging with associated inflammation in COPD
[28], suggesting that these cells could potentially be in-
volved in the onset of other inflammatory diseases in
addition to COPD. Our data also highlight the import-
ance of investigating the relative steroid resistance of the
CD28null inflammatory lymphocytes with any therapeutic
approaches, and the requirement for alternative ‘steroid-
sparing’ anti-inflammatory therapies. We have previously
shown cytotoxic/pro-inflammatory T and NKT-like cells
have increased levels of drug efflux pump, Pgp-1, and the
presence of very low dose CsA, a Pgp-1 inhibitor, resulted
in steroid sensitivity of these cells [16]. Furthermore, we
have recently shown the addition of low dose CsA in-
creased HDAC2 levels in these lymphocyte subsets
resulting in a reduction of pro-inflammatory cytokines
[9]. Taken together with our current findings suggests
that combined treatment with very low dose CsA and
standard dose prednisolone may be a drug combination
of choice to target cytotoxic/pro-inflammatory lympho-
cytes in patients with COPD. Our ex vivo assays to study
Hsp90/GCR/HDAC2 deficient pro-inflammatory lympho-
cytes may identify COPD patients that would benefit from
treatment with these combination of drugs. Further
lymphocyte phenotyping post therapy could identify ef-
fectiveness of this therapy.
Fig. 10 a Bar graph showing the inhibitory effect of 1 μM prednisolone (Pred) on IFNγ production by CD28null (grey bars) and CD28+ (clear bars)
CD8+ and CD8-T cells compared with cultures with no drug. There was a significant inhibitory effect on CD28+ compared with CD28null cells
in the presence of Pred and a significant inhibitory effect on CD28nullCD8-compared with CD28nullCD8+ cells (n = 5; median ± sem) (* p < 0.05).
b The inhibitory effect 1 μM prednisolone ± 2.5 ng/ml cyclosporine A (CsA) on IFNγ production by CD28nullCD8+ T cells compared with cultures with
no drug (n = 4; median ± sem) (*p < 0.05)
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Conclusion
Lymphocyte senescence in COPD is associated with loss
of molecular chaperone in Hsp90 in CD28nullCD8+ T
and NKT-like cells. This loss is associated with steroid
resistant pro-inflammatory lymphocytes and lung func-
tion in COPD, thus therapies aimed at targeting pro-
inflammatory senescent lymphocytes are warranted.
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